Navigation Links
World's smallest cancer detection device

Researchers at the Albert Einstein College of Medicine of Yeshiva University have received a $2 million grant from the National Cancer Institute to study tumor "microenvironments" --where tumors interact with surrounding tissues, cells and chemicals in ways that all too often encourage cancer cells to invade other areas of the body in the process known as metastasis.

With the new NCI grant, Dr. John Condeelis, co-chair of anatomy and structural biology at Einstein and the principal investigator of the newly funded program, and his Einstein colleagues will team up with researchers at the College of Nanoscale Science and Engineering (CNSE) of the University at Albany to develop a next-generation microchip that, when placed in a cancerous mass, can gather information on the presence of metastatic cells that would demand more aggressive cancer therapy.

"The NCI has placed a very high priority on understanding the 'dialogue' in tumor microenvironments that appears crucial for causing cancers to spread," says Dr. Condeelis. "This five-year Tumor Microenvironment Network grant will allow Einstein to influence the way research is carried out in this emerging and important field."

Dr. James Castracane, the project's co-investigator, who is head of the Nanobiosciences Constellation at CNSE, said, "By integrating cutting-edge science and engineering at the nanoscale level with vital biomedical research, it is our intent to provide deeper understanding of the causes of cancer metastasis and migration ? knowledge that is of critical importance in the treatment and, ultimately, prevention of cancer."

Dr. Condeelis has used the multiphoton confocal microscope to directly observe cellular interactions in the tumor microenvironment of live animal models of breast cancer. By placing an artificial blood vessel near tumors, he was able to collect motile cancer cells for study and to predict--by the presence or absence of certain signaling molecules-- whether the tumor cells have the potential to metastasize.

The Einstein and Albany researchers will use nanotechnology, which involves studying and working with material on the molecular level, to design a "microchip" version of the artificial blood vessel that Dr. Condeelis has used successfully in animals. The microchip will be assembled from nanoscale components so that several different functions can be carried out within a very small package. The goal: to implant these tiny microchips ?just two to three cells in diameter and a tenth of a millimeter in length ?in human tumors, where they would remain for days or weeks. The chips would report remotely to scanners that would "read" them on the nature of the cells that infiltrate them--in particular, on whether metastatic cells are present that would call for more aggressive cancer therapy.

In 2005, Einstein formed an alliance with UAlbany's CNSE to advance education and research in the rapidly growing fields of nanobiotechnology and nanomedicine. "This NCI grant marks a true milestone for this partnership, which combines the unique expertise and resources of both institutions to apply nanoscale principles to detect diseases and develop treatments for them," says Ira M. Millstein, chairman of the Einstein Board of Overseers. "We are committed to ensuring that the Einstein-Albany alliance will lead the nation in efforts to use nanotechnology to improve peoples' lives."


Source:Albert Einstein College of Medicine

Related biology news :

1. Worlds largest rainforest drying experiment completes first phase
2. A New Era of Hope for the Worlds Most Neglected Diseases
3. Worlds pledge to halve hunger by 2015 looks like empty promise
4. Worlds largest flower evolved from family of much tinier blooms
5. Worlds leading scientists announce creation of Encyclopedia of Life
6. New study of the worlds smallest elephant
7. Small, smaller, smallest -- The plight of the vaquita
8. Viral DNA sequence a possible trigger for breast cancer
9. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
10. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
11. Columbia research lifts major hurdle to gene therapy for cancer
Post Your Comments:

(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology: